New combination treatment for bladder cancer resistant to standard chemotherapy

This trial is testing whether rutin—a natural plant compound—combined with an immunotherapy drug called tislelizumab and standard chemotherapy can help treat bladder cancer that has not responded to initial chemotherapy. The study enrolls people whose tumors remain stable or are growing despite two rounds of standard drug treatment, and gives them two additional rounds of the medication combination. Researchers want to understand whether this treatment can shrink tumors, how safe it is, and how it works in the body.

Some people with aggressive bladder cancer do not respond well to the standard chemotherapy drugs currently used. This trial exists to see if adding these two new medications might help people whose cancers have stopped responding to standard treatment, potentially offering them another chance at controlling their disease before surgery.